Division of Johnson & Johnson
Latest From Janssen-Cilag Ltd.
Two products that the European Medicines Agency this week said should not be authorized for sale in the EU are already approved in the US.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Gilead has received the green light in the EU for marketing its newest fixed-dose HIV treatment Odefsey but its cannibalization of predecessor product Complera will not reach levels expected in the US as generic versions of older HIV combos are set to arrive earlier in the EU.
U.K. HTA rejects Celgene’s pomalidomide for treating multiple myeloma on cost grounds but waves through Bayer’s rivaroxaban for preventing blood clots in people who have had a heart attack.
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Johnson & Johnson
- Senior Management
- Contact Info
Phone: (44) 1494 567567
P.O. Box 79
High Wycombe, HP14 4HJ
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.